Matrix metalloproteinases in inflammatory bowel disease - From basic research to clinical significance;Matrix-metalloproteinasen bei chronisch-entzündlichen darmerkrankungen - Von der grundlagenforschung zur klinischen bedeutung

Zeitschrift fur Gastroenterologie

Volumn 47, Issue 8, 2009, Pages 758-769

  Rath, T ^a   Roderfeld, M ^a   Graf, J ^b   Roeb, Elke ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Chronic inflammatory bowel disease; Crohn's disease; Matrix metalloproteinases; TIMP; Ulcerative colitis

Indexed keywords

COLLAGENASE; COLLAGENASE 3; GELATINASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE;

BIOCHEMISTRY; ENTERITIS; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; INTESTINE; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL;

EID: 69849101438     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109520     Document Type: Review

References (150)

1. Woessner Jr JF. The family of matrix metalloproteinases. Ann N Y Acad Sci 1994; 732: 11-21
2. Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22: 51-86
3. Corry DB, Kiss A, Song LZ et al. Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEBJ 2004; 18: 995-997 (Pubitemid 39561503)
4. Okamoto R, Watanabe M. Cellular and molecular mechanisms of the epithelial repair in IBD. Dig Dis Sci 2005; 50 (Suppl 1): S34-S38 (Pubitemid 41380796)
5. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-629 (Pubitemid 39025047)
6. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516 (Pubitemid 33096184)
7. Arihiro S, Ohtani H, Hiwatashi N et al. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 2001; 39: 50-59 (Pubitemid 32848274)
8. Bailey CJ, Hembry RM, Alexander A et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994; 47: 113-116 (Pubitemid 24095461)
9. Baugh MD, Perry MJ, Hollander AP et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117: 814-822 (Pubitemid 29468223)
10. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174 (Pubitemid 37328786)
11. Pender SL, Tickle SP, Docherty AJ et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158: 1582-1590
12. Saarialho-Kere UK, Vaalamo M, Puolakkainen P et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996; 148: 519-526 (Pubitemid 26056736)
13. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998; 290 (Suppl): S47-S54 (Pubitemid 28502520)
14. Stallmach A, Chan CC, Ecker KW et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 2000; 47: 415-422 (Pubitemid 30670838)
15. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998; 152: 1005-1014 (Pubitemid 28173362)
16. von Lampe B, Barthel B, Coupland SE et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 63-73 (Pubitemid 30430413)
17. Castaneda FE, Walia B, Vijay-Kumar M et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005; 129: 1991-2008 (Pubitemid 41772976)
18. Di Sebastiano P, di Mola FF, Artese L et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 2001; 63: 234-239 (Pubitemid 32646303)
19. Sykes AP, Bhogal R, Brampton C et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 1535-1542 (Pubitemid 29516269)
20. Roeb E, Matern S. Matrix metalloproteinases: Promoters of tumor invasion and metastasis - A review with focus on gastrointestinal tumors. Z Gastroenterol 2001; 39: 807-813 (Pubitemid 32929103)
21. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-510
22. Bode W, Fernandez-Catalan C, Tschesche H et al. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999; 55: 639-652
23. Puente XS, Pendas AM, Llano E et al. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56: 944-949 (Pubitemid 26065382)
24. Gururajan R, Grenet J, Lahti JM et al. Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1 p36.3. Genomics 1998; 52: 101-106 (Pubitemid 28452176)
25. Velasco G, Pendas AM, Fueyo A et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 1999; 274: 4570-4576 (Pubitemid 29113351)
26. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-125 (Pubitemid 20105600)
27. Woessner Jr JF, Gunja-Smith Z. Role of metalloproteinases in human osteoarthritis. J Rheumatol Suppl 1991; 27: 99-101
28. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250
29. Li J, Brick P, O'Hare MC et al. Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. Structure 1995; 3: 541-549
30. Jenne D, Stanley KK. Nucleotide sequence and organization of the human S-protein gene: repeating peptide motifs in the "pexin" family and a model for their evolution. Biochemistry 1987; 26: 6735-6742
31. Gomis-Ruth FX, Gohlke U, Betz M et al. The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. J Mol Biol 1996; 264: 556-566 (Pubitemid 27010745)
32. Roeb E, Schleinkofer K, Kernebeck T et al. The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem 2002; 277: 50326-50332 (Pubitemid 36042181)
33. de Coignac AB, Elson G, Delneste Y et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem 2000; 267: 3323-3329 (Pubitemid 30341161)
34. Knauper V, Docherty AJ, Smith B et al. Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. FEBS Lett 1997; 405: 60-64 (Pubitemid 27130372)
35. O'Farrell TJ, Pourmotabbed T. Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site ofgelatinase B. J Biol Chem 2000; 275: 27964-27972 (Pubitemid 30688915)
36. Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA et al. Alpha4beta1 integrin and 190-kDa CD 44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008; 112: 169-178
37. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997; 15: 519-526
38. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler 1995; 376: 345-355
39. Carmeliet P, Moons L, Lijnen R et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-444 (Pubitemid 27518393)
40. Duncan ME, Richardson JP, Murray GI et al. Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur J Biochem 1998; 258: 37-43
41. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry 2002; 67: 92-98
42. Moilanen M, Sorsa T, Stenman M et al. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -3) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 2003; 42: 5414-5420 (Pubitemid 36560438)
43. Okada Y, Harris Jr ED, Nagase H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J 1988; 254: 731-741
44. Ramos-DeSimone N, Hahn-Dantona E, Sipley J et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13 066-13 076 (Pubitemid 129518506)
45. Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003; 374: 739-745 (Pubitemid 37163919)
46. Fridman R, Toth M, Pena D et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55: 2548-2555
47. Imai K, Yokohama Y, Nakanishi I et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995; 270: 6691-6697
48. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997; 15: 511-518
49. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267: 3581-3584
50. Opdenakker G, Van den Steen PE, Dubois B et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-859 (Pubitemid 32577883)
51. Pirila E, Ramamurthy NS, Sorsa T et al. Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci 2003; 48: 93-98
52. Sorsa T, Uitto VJ, Suomalainen K et al. Comparison of interstitial collagenases from human gingiva, sulcular fluid and polymorphonuclear leukocytes. J Periodontal Res 1988; 23: 386-393
53. Knauper V, Lopez-Otin C, Smith B et al. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 1544-1550
54. Daum S, Bauer U, Foss HD et al. Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 1999; 44: 17-25 (Pubitemid 29143275)
55. Otani Y, Sakurai Y, Kameyama K et al. Matrix metalloproteinase gene expression in chronic gastric ulcer: a potential role of eosinophils in perforation. J Clin Gastroenterol 1997; 25 (Suppl 1): S101-S104 (Pubitemid 28117014)
56. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998; 83: 832-840 (Pubitemid 28489080)
57. Vaalamo M, Weckroth M, Puolakkainen P et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol 1996; 135: 52-59 (Pubitemid 26225115)
58. Opdenakker G. New insights in the regulation of leukocytosis and the role played by leukocytes in septic shock. Verh K Acad Geneeskd Belg 2001; 63: 531-538
59. Von Lint P, Wielockx B, Puimege L et al. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J Immunol 2005; 175: 7642-7649 (Pubitemid 41713464)
60. Hanemaaijer R, Sorsa T, Konttinen YT et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 1997; 272: 31504-31509 (Pubitemid 28013291)
61. Bode W, Reinemer P, Huber R et al. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 1994; 13: 1263-1269 (Pubitemid 24090206)
62. Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995; 3: 527-530
63. Lovejoy B, Welch AR, Carr S et al. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 1999; 6: 217-221 (Pubitemid 29107223)
64. Rath T, Roderfeld M, Graf J et al. Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 2006; 12: 1025-1035
65. Roeb E, Arndt M, Jansen B et al. Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 2004; 19: 518-524 (Pubitemid 39445406)
66. Airola K, Karonen T, Vaalamo M et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80: 733-743 (Pubitemid 29209836)
67. Heppner KJ, Matrisian LM, Jensen RA et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-282
68. Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002; 55: 758-762 (Pubitemid 35231907)
69. Ilvesaro JM, Merrell MA Swain TM et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007; 67: 774-781
70. Merrell MA, Ilvesaro JM, Lehtonen N et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006; 4: 437-447 (Pubitemid 44197039)
71. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996; 70: 163-182
72. Banyai L, Tordai H, Patthty L. Structure and domain-domain interactions of the gelatin binding site of human 72-kilodalton type IV collagenase (gelatinase A, matrix metalloproteinase 2). J Biol Chem 1996; 271: 12003-12008 (Pubitemid 26157277)
73. Garg P, Rojas M, Ravi A et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol 2006; 177: 4103-4112 (Pubitemid 44359945)
74. Cao J, Drews M, Lee HM et al. The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. J Biol Chem 1998; 273: 34745-34752 (Pubitemid 29028165)
75. Okada A, Tomasetto C, Lutz Y et al. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol 1997; 137: 67-77 (Pubitemid 27167296)
76. Strongin AY, Collier I, Bannikov G et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338
77. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-160
78. Basset P, Okada A, Chenard MP et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997; 15: 535-541 (Pubitemid 27190028)
79. Makela M, Larjava H, Pirila E et al. Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp Cell Res 1999; 251: 67-78 (Pubitemid 29406520)
80. Turck J, Pollock AS, Lee LK et al. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996; 271: 15074-15083 (Pubitemid 26194988)
81. Xue M, Le NT, Jackson CJ. Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets 2006; 10: 143-155 (Pubitemid 43263272)
82. Lechapt-Zalcman E, Pruliere-Escabasse V, Advenier D et al. Transforming growth factor-beta1 increases airway wound repair via MMP-2 upregulation: a new pathway for epithelial wound repair? Am J Physiol Lung Cell Mol Physiol 2006; 290: L1277-L1282
83. Kirkegaard T, Hansen A, Bruun E et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004; 53: 701-709 (Pubitemid 38561449)
84. Kaur K, Zhu K, Whittemore MS et al. Identification of the active site of gelatinase B as the structural element sufficient for converting a protein to a metalloprotease. Biochemistry 2002; 41: 4789-4797 (Pubitemid 34298645)
85. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003; 28: 12-24
86. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571-579
87. Roeb E, Dietrich CG, Winograd R et al. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 2001; 92: 2680-2691 (Pubitemid 33049453)
88. Liabakk NB, Talbot I, Smith RA et al. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190-196 (Pubitemid 26010399)
89. Baugh MD, Evans GS, Hollander AP et al. Expression of matrix metalloproteases in inflammatory bowel disease. Ann N Y Acad Sci 1998; 859: 249-253 (Pubitemid 29021034)
90. Tarlton JF, Whiting CV, Tunmore D et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol 2000; 157: 1927-1935
91. Manfredi MA, Zurakowski D, Rufo PA et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1091-1096
92. Medina C, Videla S, Radomski A et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 2003; 284: G116-G122 (Pubitemid 36076256)
93. Medina C, Santana A, Paz MC et al. Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol 2006; 79: 954-962 (Pubitemid 44835582)
94. Fini ME, Parks WC, Rinehart WB et al. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol 1996; 149: 1287-1302
95. Mohan R, Chintala SK, Jung JC et al. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J Biol Chem 2002; 277: 2065-2072 (Pubitemid 34968789)
96. Alexander JS, Elrod JW. Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 2002; 200: 561-574
97. Behzadian MA, Wang XL, Windsor LJ et al. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci 2001; 42: 853-859
98. Scott KA, Arnott CH, Robinson SC et al. TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene 2004; 23: 6954-6966
99. Van den Steen PE, Proost P, Wuyts A et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96: 2673-2681 (Pubitemid 30770359)
100. Matsubara M, Zieske JD, Fini ME. Mechanism of basement membrane dissolution preceding corneal ulceration. Invest Ophthalmol Vis Sci 1991; 32: 3221-3237
101. Stetler-Stevenson WG, Krutzsch HC, Wacher MP et al. The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem 1989; 264: 1353-1356
102. Breathnach R, Matrisian LM, Gesnel MC et al. Sequences coding for part of oncogene-induced transin are highly conserved in a related rat gene. Nucleic Acids Res 1987; 15: 1139-1151 (Pubitemid 17012899)
103. Fu L, Ishizuya-Oka A, Buchholz DR et al. A causative role of stromelysin-3 in extracellular matrix remodeling and epithelial apoptosis during intestinal metamorphosis in Xenopus laevis. J Biol Chem 2005; 280: 27856-27865 (Pubitemid 41076902)
104. Pendas AM, Knauper V, Puente XS et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997; 272: 4281-4286 (Pubitemid 27078499)
105. Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H et al. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest 1994; 94: 79-88 (Pubitemid 24218079)
106. Li CK, Pender SL, Pickard KM et al. Impaired immunity to intestinal bacterial infection in stromelysin-1 (matrix metalloproteinase-3)-deficient mice. J Immunol 2004; 173: 5171-5179
107. Gordon JN, Pickard KM, Di Sabatino A et al. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 195-203 (Pubitemid 351288040)
108. Pender SL, Croucher PJ, Mascheretti S et al. Transmission disequilibrium test of stromelysin-1 gene variation in relation to Crohn's disease. J Med Genet 2004; 41: e112
109. Welgus HG. Stromelysin: structure and function. Agents Actions Suppl 1991; 35: 61-67
110. Zhang K, Kramer RH. Laminin 5 deposition promotes keratinocyte motility. Exp Cell Res 1996; 227: 309-322 (Pubitemid 26320173)
111. Airola K, Reunala T, Salo S et al. Urokinase plasminogen activator is expressed by basal keratinocytes before interstitial collagenase, stromelysin-1, and laminin-5 in experimentally induced dermatitis herpetiformis lesions. J Invest Dermatol 1997; 108: 7-11 (Pubitemid 27019835)
112. Madlener M, Mauch C, Conca W et al. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J 1996; 320 (Pt 2): 659-664 (Pubitemid 26417794)
113. Newell KJ, Witty JP, Rodgers WH et al. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994; 10: 199-206
114. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839 (Pubitemid 36542523)
115. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996; 28: 123-136
116. Miyazaki K, Hattori Y, Umenishi F et al. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res 1990; 50: 7758-7764
117. Wielockx B, Libert C, Wilson C. Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation? Cytokine Growth Factor Rev 2004; 15: 111-115
118. Salmela MT, Pender SL, Karjalainen-Lindsberg ML et al. Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol 2004; 39: 1095-1104
119. Matsuno K, Adachi Y, Yamamoto H et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 2003; 38: 348-354 (Pubitemid 36626270)
120. Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen 1999; 7: 423-432
121. Wilson CL, Ouellette AJ, Satchell DP et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286: 113-117
122. Adachi Y, Yamamoto H, Itoh F et al. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999; 45: 252-258 (Pubitemid 29333775)
123. Masaki T, Matsuoka H, Sugiyama M et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001; 84: 1317-1321 (Pubitemid 32522098)
124. Newell KJ, Matrisian LM, Driman DK. Matrilysin (matrix metalloproteinase-7) expression in ulcerative colitis-related tumorigenesis. Mol Carcinog 2002; 34: 59-63
125. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268: 23824-23829 (Pubitemid 23335353)
126. Shipley JM, Wesselschmidt RL, Kobayashi DK et al. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 1996; 93: 3942-3946
127. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373-384
128. Udayakumar TS, Chen ML, Bair EL et al. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res 2003; 63: 2292-2299
129. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000; 6: 391-407
130. Malhotra S, Newman E, Eisenberg D et al. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression. Dis Colon Rectum 2002; 45: 537-543 (Pubitemid 34407733)
131. Gomez DE, Alonso DF, Yoshiji H et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122 (Pubitemid 27455388)
132. Kasahara A, Hayashi N, Mochizuki K et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997; 26: 574-583 (Pubitemid 27112723)
133. O'Connell JP, Willenbrock F, Docherty AJ et al. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem 1994; 269: 14967-14973 (Pubitemid 24198336)
134. Roeb E, Graeve L, Hoffmann R et al. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology 1993; 18: 1437-1442 (Pubitemid 23348434)
135. Gatsios P, Haubeck HD, LE et al. Oncostatin M differentially regulates tissue inhibitors of metalloproteinases TIMP-1 and TIMP-3 gene expression in human synovial lining cells. Eur J Biochem 1996; 241: 56-63 (Pubitemid 26342971)
136. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 318: 933-938 (Pubitemid 44268297)
137. Louis E, Ribbens C, Godon A et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 241-246 (Pubitemid 30304217)
138. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005; 26: 379-390 (Pubitemid 41225360)
139. Meijer MJ, Mieremet-Ooms MA, Sier CF et al. Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn's disease. Inflamm Bowel Dis 2009; 15: 84-92
140. McKaig BC, McWilliams D, Watson SA et al. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003; 162: 1355-1360 (Pubitemid 36350679)
141. Di Sabatino A, Pender SL, Jackson CL et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007; 133: 137-149 (Pubitemid 47031137)
142. Hemmann S, Graf J, Roderfeld M et al. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on antifibrotic strategies. J Hepatol 2007; 46: 955-975 (Pubitemid 46529049)
143. De Lano WL. The PyMOL User's Manual. San Carlos, CA, USA, 2002
144. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? lnflamm Bowel Dis 2007; 13: 97-107
145. Baricos WH, Murphy G, Zhou YW et al. Degradation of glomerular basement membrane by purified mammalian metalloproteinases. Biochem J 1988; 254: 609-612 (Pubitemid 18213301)
146. Murphy G, Cockett MI, Ward RV et al. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277 (Pt 1): 277-279
147. Nguyen Q, Murphy G, Roughley PJ et al. Degradation of proteoglycan aggregate by a cartilage metalloproteinase. Evidence for the involvement of stromelysin in the generation of link protein heterogeneity in situ. Biochem J 1989; 259: 61-67
148. Okada Y, Nakanishi I. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 ('gelatinase') by human neutrophil elastase and cathepsin G. FEBS Lett 1989; 249: 353-356 (Pubitemid 19143491)
149. Chandler S, Cossins J, Lury J et al. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Commun 1996; 228: 421-429 (Pubitemid 26396090)
150. Gronski Jr TJ, Martin RL, Kobayashi DK et al. Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem 1997; 272: 12189-12194